Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 17/20 | 0.78 |
| ▸ | CCR2 | P41597 | 1/20 | 0.78 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | HTT | P42858 | 2/20 | 0.77 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAPT | P10636 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12221304 | 0.91 | CCR9 (0.66) | CCR9CCR2LMNAHTTHSD17B2 | |
| SCHEMBL2530947 | 0.90 | LMNA (0.78) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL13805672 | 0.90 | CCR9 (0.73) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL28006 | 0.89 | LMNA (0.86) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL2534068 | 0.89 | LMNA (0.71) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL343333 | 0.89 | CCR9 (0.82) | CCR9CCR2 | |
| SCHEMBL12221311 | 0.89 | CCR9 (0.82) | CCR9CCR2LMNAHTTTP53 | |
| Vercirnon SCHEMBL342225 | 0.88 | CCR9 (1.00) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL15761702 | 0.88 | CCR9 (0.84) | CCR9CCR2LMNAHTTTP53 | |
| SCHEMBL15802910 | 0.88 | CCR9 (0.84) | CCR9CCR2LMNAHTTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 118 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2402310-A1 | CCR9 inhibitors and methods of use thereof | Millennium Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| EP-2399903-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2011-12-28 | — | — | EP | claimed |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2010-12-23 | — | — | US | claimed |
| US-7741519-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. (US) | 2010-06-22 | — | — | US | claimed |
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNNIUM PHARMACEUTICALS, INC. (US) | 2010-04-15 | — | — | US | claimed |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | UNGASHE SOLOMON | 2008-10-23 | — | — | US | claimed |
| EP-1567486-B1 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX INC (US) | 2008-01-16 | — | — | EP | claimed |
| US-7227035-B2 | Bis-aryl sulfonamides | CHEMOCENTRYX (US) | 2007-06-05 | — | — | US | claimed |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2007-03-22 | — | — | US | claimed |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2006-07-27 | — | — | US | claimed |
| EP-1507756-A4 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2006-03-15 | — | — | EP | claimed |
| JP-2005526857-A | — | — | 2005-09-08 | — | — | JP | claimed |
| EP-1507756-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2005-02-23 | — | — | EP | claimed |
| WO-2003099773-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-04 | — | — | WO | claimed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | MILLENNIUM PHARMECEUTICALS INC (US) | 2016-03-10 | — | — | US | disclosed |
| WO-2004085384-A2 | BIS-ARYL SULFONAMIDES | CHEMOCENTRYX (US) | 2004-10-07 | — | — | WO | disclosed |
| US-20040167113-A1 | Bis-aryl sulfonamides | CHEMOCENTRYX, INC. | 2004-08-26 | — | — | US | disclosed |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | MILLENNIUM PHARMACEUTICALS, INC. | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093802-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
| US-20060167251-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
| US-20040167113-A1 | Bis-aryl sulfonamides | CCR2, CXCR2, CCL2 | CCR9 14/4885CCR2 1/4885LMNA 4769/4885 |
| US-20160068479-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
| US-20040038976-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
| US-20080261966-A1 | BIS-ARYL SULFONAMIDES | CCR2, CXCR2, CCL2 | CCR9 14/4885CCR2 1/4885LMNA 4769/4885 |
| US-20070066823-A1 | CCR9 inhibitors and methods of use thereof | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
| US-20100324093-A1 | CCR9 INHIBITORS AND METHODS OF USE THEREOF | CCR9, CCR1, CCR4 | CCR9 1/4885CCR2 10/4885LMNA 3548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.